Literature DB >> 8871440

Review article: the medical management of Crohn's disease.

E Elton1, S B Hanauer.   

Abstract

The choice of medical therapies for Crohn's disease continues to grow. Although our understanding of the mechanisms of the disease is incomplete, increasing knowledge of the pathogenesis of inflammation in general and Crohn's disease in particular allows targeting of therapies at various points in the immunoinflammatory cascade. In addition, the division of Crohn's disease into subtypes by location, aggressiveness, and the presence or absence of perianal and fistulizing disease allows the tailoring of medical therapy to the individual patient. For those patients with moderate to severe symptoms or frequent flares of disease activity, and those who have required surgical resection, maintenance therapy can substantially reduce the rate of recurrence. Despite these advances, available medical therapies for Crohn's disease remain imperfect, as evidenced by their sometimes substantial toxicities and the continued frequent need for surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871440     DOI: 10.1111/j.1365-2036.1996.tb00173.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

1.  Drug-induced fibrosing colonopathy in inflammatory bowel disease after 5-ASA?

Authors:  H Allgayer; P Böhne; W Kruis
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

Review 2.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

3.  Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine.

Authors:  W D Heizer; J L Peterson
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.